S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$55.83
+0.40 (+0.72%)
(As of 08/8/2022 05:23 PM ET)
Add
Compare
Today's Range
$55.14
$58.51
50-Day Range
$36.01
$55.43
52-Week Range
$34.90
$98.67
Volume
508,425 shs
Average Volume
455,197 shs
Market Capitalization
$2.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.67

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
57.0% Upside
$87.63 Price Target
Short Interest
Bearish
11.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.30mentions of Arvinas in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.36) to ($4.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

829th out of 1,293 stocks

Pharmaceutical Preparations Industry

399th out of 619 stocks

ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Jefferies Financial Group began coverage on Arvinas in a research note on Tuesday, June 21st. They issued a "hold" rating and a $42.00 target price for the company. Piper Sandler lowered their price target on shares of Arvinas from $116.00 to $76.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. Cantor Fitzgerald decreased their price target on shares of Arvinas from $140.00 to $115.00 in a report on Friday. Citigroup cut their price objective on shares of Arvinas to $103.00 and set a "buy" rating for the company in a research report on Friday, May 20th. Finally, Wedbush cut shares of Arvinas from an "outperform" rating to a "neutral" rating and set a $43.00 price objective on the stock. in a research note on Monday, May 9th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and an average target price of $86.67.

Arvinas Trading Up 7.8 %

Shares of NASDAQ:ARVN opened at $55.43 on Monday. The stock has a market capitalization of $2.95 billion, a PE ratio of -12.43 and a beta of 2.00. Arvinas has a 12-month low of $34.90 and a 12-month high of $103.53. The stock's fifty day simple moving average is $46.12 and its two-hundred day simple moving average is $56.66.

Arvinas (NASDAQ:ARVN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.28). The business had revenue of $31.30 million during the quarter, compared to analysts' expectations of $23.71 million. Arvinas had a negative net margin of 255.97% and a negative return on equity of 30.11%. Arvinas's revenue for the quarter was up 469.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.03) EPS. On average, equities analysts predict that Arvinas will post -4.36 earnings per share for the current fiscal year.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

SVB Leerink Cuts Arvinas (NASDAQ:ARVN) Price Target to $89.00
Recap: Arvinas Q2 Earnings - Benzinga
Arvinas Inc - Stock Analysis
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
8/04/2022
Today
8/08/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$87.63
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+55.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

Net Income
$-191,000,000.00
Net Margins
-255.97%
Pretax Margin
-247.24%

Debt

Sales & Book Value

Annual Sales
$46.70 million
Book Value
$14.78 per share

Miscellaneous

Free Float
51,726,000
Market Cap
$2.97 billion
Optionable
Not Optionable
Beta
2.00

Key Executives

  • Dr. John G. Houston Ph.D. (Age 62)
    CEO, Pres & Director
    Comp: $1.07M
  • Mr. Sean A. Cassidy CPA (Age 52)
    CPA, M.B.A., CFO & Treasurer
    Comp: $667.73k
  • Dr. Ian Taylor Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $686.8k
  • Dr. Ronald A. Peck
    Chief Medical Officer
  • Mr. Jeff Boyle
    VP of Investor Relations
  • Mr. Matthew Batters J.D. (Age 46)
    Gen. Counsel
  • Dr. Randy Teel Ph.D. (Age 43)
    Sr. VP of Corp. & Bus. Devel.
  • Mr. Steve Weiss (Age 52)
    Sr. VP & Chief HR Officer
  • Dr. John A. Grosso Ph.D. (Age 65)
    Sr. VP of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 54)
    Sr. VP of Neuroscience & Platform Biology













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2022?

17 brokers have issued twelve-month price targets for Arvinas' shares. Their ARVN stock forecasts range from $42.00 to $135.00. On average, they anticipate the company's share price to reach $87.63 in the next twelve months. This suggests a possible upside of 55.9% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How has Arvinas' stock price performed in 2022?

Arvinas' stock was trading at $82.14 at the beginning of the year. Since then, ARVN stock has decreased by 31.6% and is now trading at $56.22.
View the best growth stocks for 2022 here
.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Thursday, August, 4th. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.04) by $0.28. The company had revenue of $31.30 million for the quarter, compared to analysts' expectations of $23.71 million. Arvinas had a negative trailing twelve-month return on equity of 31.16% and a negative net margin of 255.97%. The firm's quarterly revenue was up 469.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.03) earnings per share.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam S.C.A. (0.93%), Brown Advisory Inc. (0.54%), Emerald Advisers LLC (0.50%), Emerald Mutual Fund Advisers Trust (0.43%), Connor Clark & Lunn Investment Management Ltd. (0.23%) and Versor Investments LP (0.14%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $56.22.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $2.99 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.46) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.